MAP2K7 and non-small cell lung carcinoma: Similarly, recent preclinical studies have suggested that NSCLC cells made osimertinib-resistant through different mechanisms maintain their growth in part by aberrant EGFR-independent activation of the MAPK pathway downstream EGFR and can regain drug-sensitivity by combining osimertinib with a MEK-inhibitor [292,293].